Late Stage Cancer
November 13, 2024
Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer
https://www.onclive.com/view/zolbetuximab-plus-chemotherapy-offers-survival-benefits-in-treatment-naive-her2-gastric-gej-cancer
September 3, 2024
Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma
https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-024-03382-w
September 1, 2024
Nivolumab Plus Neoadjuvant Chemoradiation Fails to Enhance pCR Rate in Esophageal/GEJ Adenocarcinoma
https://www.onclive.com/view/nivolumab-plus-neoadjuvant-chemoradiation-fails-to-enhance-pcr-rate-in-esophageal-gej-adenocarcinoma
July 26, 2024
ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer
https://ascopost.com/issues/july-25-2024/esopec-trial-flot-protocol-proves-superior-to-cross-regimen-in-locally-advanced-esophageal-cancer/
May 21, 2024
The Drug Tevimbra Now Approved For Use in Esophageal Cancer– Finally Some Help For Patients In Great Need
https://www.survivornet.com/articles/the-fda-approves-tevimbra-for-use-in-esophageal-cancer/
April 26, 2024
Aspirin Linked to Lower Metastasis in Esophageal, Colorectal Cancers
https://www.curetoday.com/view/aspirin-linked-to-lower-metastasis-in-esophageal-colorectal-cancers
April 4, 2024
FLOT vs CROSS in Resectable GEJ Adenocarcinoma: Which Regimen is Best?
https://www.targetedonc.com/view/flot-vs-cross-in-resectable-gej-adenocarcinoma-which-regimen-is-best-
March 28, 2024
atients With Esophageal Cancer Have ‘More Options’ With Tevimbra
https://www.curetoday.com/view/patients-with-esophageal-cancer-have-more-options-with-tevimbra